⚠ Medical Inflation and a Crowded FieldModerate threat

The very attractiveness of private health is its risk: it is a magnet for competition and a hostage to medical-cost inflation. PZU Zdrowie competes with entrenched private-medical operators like Medicover and Lux Med, well-run specialists who got there first in much of the corporate market, and the fight for clinic capacity, doctors, and employer contracts is intense. Being a large insurer does not automatically make you a great healthcare operator — running clinics well is a different, hands-on business.

And health cover carries a treacherous cost dynamic. Medical inflation — the rising price of doctors, procedures, and drugs — can outrun the premiums written years earlier, squeezing margins the way it has punished health insurers the world over. Scaling clinic capacity is capital-intensive and slow, and mispricing multi-year health plans against runaway costs is an easy way to turn a growth engine into a loss center. The opportunity is real; so is the operational difficulty, and PZU is a challenger here, not the incumbent — the ~44%-share position it enjoys in life¹ — that it is in insurance.